Latest Conference Articles

Real world results garnered positive outcomes in the historically difficult-to-treat population.

Physicians looking to provide effective treatment to co-infected patients mustn't overlook uncontrolled viremia or substance abuse, according to a new study.

The CDC and local agencies have partnered to combat the outbreak, but it’s not under control yet.

Tom Chiller, MD, MPH, Mycotic Diseases Branch, Centers for Disease Control and Prevention, talks about treatment options for Candida auris and multi-drug resistant treatment options.

Tom Chiller, MD, MPH, Mycotic Diseases Branch, Centers for Disease Control and Prevention, discusses Candida auris.

Paul Ananth Tambyah, MD, Dept. of Medicine, Infectious Disease, National University of Singapore, provides an overview of infection control approach for travelers with either epidemic or endemic diseases from various parts of the world.

Individuals engaged in riskier behaviors and relationships appear to be more inclined to continue taking treatment.

Treating opioid use disorder can reduce mortality and curb spreading infections in people who use drugs.

The sc2Wear Infusor allows the opportunity to deliver furosemide subcutaneously and at home, to keep HF patients in need of diuresis out of the hospital.

New technologies are creating opportunities for physicians to provide better treatment and differentiate themselves in a crowded health care space.

Physicians should remain vigilant in counseling their patients away from activities that pose a high risk of head injuries.

Our understanding of autism has improved significantly over the past decade. Among several discoveries, we now know that children with autism interpret faces differently than their peers without the condition.

In response to patient concerns about dosing options and duration of effect, researchers at Shire Pharmaceuticals created Mydayis for the treatment of ADHD symptoms.

Over the last decade, physicians have gained significant ground in their understanding of autism. Here's what we know now.

Psychedelics like psilocybin have been receiving attention from psychiatrists on and off for decades. Here's what we've learned, and what's on the horizon.

When asked about an ideal medication, most survey respondents said such a drug would last all day.

The ROPA-DOP trial showed that low-dose dopamine had an insignificant impact on patient renal function, nor a significant trend toward greater diuresis.

Scott Solomon, MD, and Alvin Chandra, MD, discuss the findings of the PARADIGM-HF and QoL trial, and sacubitril's effect on HF patients quality of life.

Michael Felker, MD, talks about the results of the GUIDE-IT trial and the use of natriuretic peptide-guided therapy for patients with HFrEF.

Parental rejection, abandonment, physical and sexual abuse double the victim's rates of depression, inflammation, metabolic disorders and chronic medical illnesses.

Patients struggling with addiction can be difficult to treat. Following best practices can help simplify a complex process.

Patients ask about side effects a lot, but physicians aren't always keen to listen, according to Michael Thase, MD. Here's why they should.

Ketamine shows huge promise in patients with depression. Here's why it may become the next big breakthrough treatment option in depressed patients.

Lisa Rathman, MSN, of Lancaster General Hospital, discusses the benefits of subcutaneous furosemide in nursing homes and facilities outside the hospital.

Gregg Fonarow, MD; David Aguilar, MD; Rob Mentz, MD; and James Januzzi, MD, discuss the unexpected and exciting use of SGLT-2 inhibitors to treat heart failure.

Rob Mentz, MD, of Duke University Medical School, discusses the CANVAS trial and the pursuit of using SGLT-2 inhibitors to treat heart failure.

The drug showed improved symptoms across multiple doses in a 6-month study.

Gregg Fonarow, MD, of UCLA, discusses the vital importance of preventing HF in ways outside of just the available treatment options.

Mandeep Mehra, MD, President of the HFSA, discusses one of the HFSA annual meeting's themes: the prophylaxis of heart failure through behavioral and dietary adjustments.

Rob Mentz, MD; David Aguilar, MD; Mandeep Mehra, MD; and Lisa Rathman, MSN, discussed the use of team-based care in heart failure, a condition plagued by comorbidities and often treated by multiple specialists.